Liquidia Corporation is a US-based biopharmaceutical company that creates products to address unmet patient needs. Its focus is on treating pulmonary arterial hypertension, and its product candidates include YUTREPIA, a dry powder formulation of treprostinil which can be inhaled. The company was founded in 2004 and is headquartered in Morrisville, North Carolina.